Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Feng Chi BiotechROCO:6744 79 EV-to-EBITDA is 1.99 as of Sep. 04, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates ROCO:6744 with a GF Score™ of 79/100 and a GF Value™ of NT$18.04 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 403 Biotechnology companies, Feng Chi Biotech ranks better than 77.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Feng Chi Biotech's enterprise value is NT$47.8 Mil.
Feng Chi Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$24.0 Mil. Therefore, Feng Chi Biotech's EV-to-EBITDA for today is 1.99.
The historical rank and industry rank for Feng Chi Biotech's EV-to-EBITDA or its related term are showing as below:
ROCO:6744'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.39 Med: 4 Max: 15.41
Current: 1.99
During the past 10 years, the highest EV-to-EBITDA of Feng Chi Biotech was 15.41. The lowest was 1.39. And the median was 4.00.
ROCO:6744's EV-to-EBITDA is ranked better than 77.17% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:6744: 1.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Feng Chi Biotech (ROCO:6744) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Feng Chi Biotech's PE Ratio (TTM) for today is calculated as:
Feng Chi Biotech's share price for today is NT$14.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feng Chi Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.643.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Feng Chi Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6744 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Feng Chi Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's EV-to-EBITDA falls into.
Feng Chi Biotech's current Enterprise Value is NT$47.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feng Chi Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech (ROCO:6744) has a EV-to-EBITDA of 1.99 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Feng Chi Biotech. This is 50% below median its historical median of 4.00. Over the past decade, Feng Chi Biotech's EV-to-EBITDA has ranged from 1.39 to 15.41. According to the industry distribution chart, Feng Chi Biotech ranks #92 out of 403 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Feng Chi Biotech's EV-to-EBITDA too high?
Feng Chi Biotech's current EV-to-EBITDA of 1.99 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 15.41. The Biotechnology industry median EV-to-EBITDA is 13.70. Feng Chi Biotech's value of 1.99 is 85.5% below this industry median. Based on the distribution chart, Feng Chi Biotech ranks #92 out of 403 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #92 out of 403 companies for EV-to-EBITDA. This places Feng Chi Biotech in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.70. Feng Chi Biotech's value of 1.99 is 85.5% below this benchmark. Historically, Feng Chi Biotech's own EV-to-EBITDA has ranged from 1.39 to 15.41 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 13.70, Feng Chi Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Feng Chi Biotech's current EV-to-EBITDA of 1.99 is 85.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Feng Chi Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feng Chi Biotech's current EV-to-EBITDA is 1.99, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.04, compared to a current price of NT$14.00 — trading 22.4% below its estimated fair value. The current EV-to-EBITDA is 1.99, which is 50% below median its 10-year median of 4.00 and 85.5% below the Biotechnology industry median of 13.70. Feng Chi Biotech's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current EV-to-EBITDA is 1.99 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$14.00 is trading 22.4% below its estimated GF Value™ of NT$18.04.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
EV-to-EBITDA: 1.99 (50% below median its 10-year median of 4.00)
GF Value™: NT$18.04 vs. price of NT$14.00 (22.4% below fair value)
Industry Position: 85.5% below the Biotechnology median (#92 of 403)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
79GF Score
Get the complete analysis for ROCO:6744
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
